Objective-RalA and RalB GTPases are important regulators of cell growth, cancer metastasis, and granule secretion. The purpose of this study was to determine the role of Ral GTPases in platelets with the use of platelet-specific gene-knockout mouse models. Approach and Results-This study shows that platelets from double knockout mice, in which both GTPases have been deleted, show markedly diminished (≈85% reduction) P-selectin translocation to the surface membrane, suggesting a critical role in α-granule secretion. Surprisingly, however, there were only minor effects on stimulated release of soluble α-and δ-granule content, with no alteration in granule count, morphology, or content. In addition, their expression was not essential for platelet aggregation or thrombus formation. However, absence of surface P-selectin caused a marked reduction (≈70%) in platelet-leukocyte interactions in blood from RalAB double knockout mice, suggesting a role for platelet Rals in platelet-mediated inflammation. Conclusions-Platelet Ral GTPases primarily control P-selectin surface expression, in turn regulating platelet-leukocyte interaction. Ral GTPases could therefore be important novel targets for the selective control of platelet-mediated immune cell recruitment and inflammatory disease. Visual Overview-An online visual overview is available for this article. (Arterioscler Thromb Vasc Biol. 2018;38: 787-800.
R
al GTPases, RalA and RalB, are Ras-like small GTPases that are important mediators of tumor growth and metastasis, with Ral inhibitor compounds currently being developed as novel anticancer agents. [1] [2] [3] In addition, they have key roles to play in membrane trafficking and secretion via interactions with their effector, the exocyst complex. 4, 5 Widely expressed in human tissues, the exocyst is an octameric protein complex involved in tethering secretory vesicles to plasma membranes, preceding SNARE (N-ethylmaleimide-sensitive factor attachment protein receptor) complex formation and exocytosis. 5, 6 In platelets, regulatory GTPases such as Rab27b, RhoA/G, and Rap1b all play major roles in platelet function, acting as molecular switches in signaling pathways, themselves being regulated by GEFs (guanine exchange factors) and GAPs (GTPase activating proteins). [7] [8] [9] Rals have been shown to be expressed in platelets, but are yet to be extensively investigated in these cells.
Platelet activation at sites of vascular damage leads to the release of over 300 bioactive molecules from distinct secretory granules. 10, 11 Dense (δ) granules predominantly contain small molecules with platelet-activating properties, aiding recruitment of platelets to a growing thrombus. 12 The contents and roles of α-granules are more varied, with studies highlighting roles for α-granule releasates in immune responses and wound healing, as well as angiogenesis and tumor metastasis. 13 Importantly, α-granules also express cell adhesion molecules such as P-selectin on their membranes which translocate to the platelet membrane on granule fusion, mediating interaction with leukocytes-regulating their extravasation into tissues. 14, 15 As the functions associated with platelet releasates are so varied, platelet secretion is a tightly regulated process. 16, 17 Little is known about the role of platelet Ral GTPases. Previous studies have shown that both RalA/B become activated on platelet stimulation in a Ca 2+ -dependent manner, and the use of functional blocking antibodies in a permeabilized platelet system highlighted roles for Rals in δ-granule secretion via exocyst interactions. 18, 19 However, because of a lack of knockout models and the limitations associated with the use of permeabilized platelet systems, elucidating fully the roles of platelet Rals has not previously been possible.
In this study, we have generated the first murine plateletspecific knockouts for RalA, RalB, and both together (RalAB), to definitively investigate the roles of these GTPases in platelets. Results show that the presence of at least 1 Ral isoform is necessary for P-selectin expression on the platelet membrane, with RalAB double knockout (DKO) platelets showing an 85% reduction in P-selectin expression in response to platelet stimulation. Surprisingly, however, release of α-granule cargo is largely unaltered in the RalAB DKO, pointing to the possibility that Ral GTPases do not control all aspects of α-granule secretion. Furthermore, δ-granule secretion was only marginally reduced in the RalAB DKO, with no significant effect observed in aggregation or thrombus formation assays. The markedly diminished P-selectin exposure in the absence of RalAB leads to a substantial reduction in platelet-leukocyte (PI-Leuk) interactions. The Pf4 (platelet factor 4)-Cre + RalA/ B flox mice also show a delay in the onset of dextran sulfate sodium (DSS)-induced ulcerative colitis symptoms in vivo. Taken together, these results suggest that platelet Rals may contribute to platelet-mediated immune responses and targeting them may provide a novel and selective approach to the treatment of certain inflammatory diseases, while also providing caution about the use of Ral inhibitors in the treatment of cancer. 2 (RalAB WT) . Eight-to 24-week age-and sex-matched mice were used in all experiments, with data from male and female mice analyzed and presented together. The local ethics committee at the University of Bristol, United Kingdom, approved all animal studies, and mice were bred for this purpose under the UK Home Office project license PPL30/2908.
Materials and Methods

Materials
Human and Mouse Platelet Preparation
Human blood was obtained from healthy volunteers in accordance with the local research ethics committee at the University of Bristol (LREC number E5736). Animals were euthanized by CO 2 asphyxiation, and blood was drawn from the inferior (caudal) vena cava as previously described. 21 Platelets were prepared as previously described 22 and rested for 30 minutes at 30°C in the presence of 10 μmol/L indomethacin and 0.02 U/mL of apyrase before stimulation. For flow cytometry and releasate studies, washed mouse platelets were recalcified to a final concentration of 1 mmol/L with CaCl 2 1 minute before stimulation.
Generation of GST Fusion Proteins
pGEX4T1-GST-RalBP1 and Ral mutant constructs were generated as previously described. 18 Ral mutants were polymerase chain reaction 
Pull-Down Assays
Three hundred microliters of human platelets at 4×10 8 platelets/mL were stimulated with indicated agonists before lysis with 2× NP40 buffer (20% glycerol, 2% NP40, 400 mmol/L NaCl, 50 mmol/L HEPES, 5 mmol/L MgCl 2 , 2 μmol/L microcystin-LR, 1×complete mini EDTA (ethylenediaminetetraacetic acid)-free protease inhibitor tablet/5 mL). Lysates were placed on ice for 10 minutes with 30 μL removed and added to 4×LDS sample buffer supplemented with 50 mmol/L dithiothreitol to be used as a loading control. Remaining lysate was clarified by centrifugation before rotation for 1 hour at 4°C with 25 μL of GST-bead slurry. Beads were washed with ice-cold 1×NP40 buffer 3× before addition of 20 μL 2×LDS sample buffer with dithiothreitol. Input and pull-down samples were incubated at 80°C for 10 minutes before analysis by immunoblotting.
Electrophoresis and Immunoblotting
Appropriate percentage tris-glycine SDS-PAGE (sodium dodecyl sulfate-polyacrylamide) gels were used to run platelet proteins. Gels were then transferred onto either Immobilon P or FL depending on the developer in use (P for an enhanced chemiluminescent system, FL for a fluorescence system). Membranes were blocked for an hour at room temperature in 5% BSA (bovine serum albumin) before subsequent incubation with primary and secondary antibodies between several wash stages. Proteins were either detected using an enhanced chemiluminescent and film detection system or a fluorescence-based Li-Cor Odyssey CLx (Lincoln).
Quantification of Integrin α IIb β 3 Activation and P-Selectin Expression
Flow cytometry analysis of platelets was performed as previously described. 23 Samples were analyzed on a Becton Dickson Biosciences FACScan flow cytometer, with raw data exported and analyzed using Flowing Software.
Quantification of PF4 and TGF-β Secretion
Washed mouse platelets at 2×10 8 platelets/mL were stimulated with indicated concentrations of agonist for designated time periods at 37°C, before centrifugation at 650g for 1 minute to isolate releasate. Control total samples were generated by lysing unstimulated platelets with an equal volume of 1% Triton-X before 3 cycles of snap freezing. For PF4 studies, releasate and total samples were diluted 1/250 and 1/500 in reagent diluent (0.5% BSA, 0.05% TWEEN in PBS). In TGF-β studies, releasate and total samples were diluted 1/20 and 1/40, respectively. Determination of PF4 and TGF-β levels was achieved with the use of appropriate kits, where concentration of analytes was achieved with the generation of a standard curve. All kits were used according to the manufacturer's protocol, with colorimetric readout at 450/540 nm achieved with the use of a TECAN Infinite 200 PRO microplate reader (Reading, United Kingdom).
Antibody Microarray Analysis of Platelet Releasate
Eight hundred microliters aliquots of mouse platelets at 4×10 8 platelets/mL were stimulated with 3 μg/mL CRP-XL for 10 minutes at 37°C, before centrifugation at 650g for 10 minutes to isolate releasate. Seven hundred microliters of releasate was supplemented with 300 μL Array Buffer 6 and 500 μL Array Buffer 4 before completion of the assay according to manufacturer's instruction. Proteins were detected with an enhanced chemiluminescent and film system before quantification with ImageJ.
Immunofluorescence
Platelets were prepared as previously described with minor modifications. 24 Mouse platelet-rich plasma was fixed with 4% paraformaldehyde and 1% BSA in PBS for 15 minutes before being spotted onto coverslips. Platelets were incubated in 100% humidity at 37°C for 90 minutes before rinsing with PBS and permeabilization with 0.2% Triton-X. Platelets were blocked with 0.2% BSA for 30 minutes before immunostaining with designated antibodies or IgG controls overnight, with unstained and secondary-only samples also used as controls. Coverslips were mounted before images were acquired with a Leica SP5-AOBS confocal laser scanning microscope attached to a Leica SM I6000 inverted epifluorescence microscope. Deconvolution of images and post-processing was achieved with the use of Huygens Professional and Volocity.
In Vitro Thrombus Formation
Quantification of thrombus formation on collagen under flow was performed as previously described. 25 In brief, ibidi μ-Slide VI 0.1 chips were coated with 50 μg/mL collagen for 2 hours before being flushed and blocked with 2% fatty acid-free BSA prepared in HEPES Tyrode buffer. Mouse blood was taken as above and anticoagulated with 2000 U/mL heparin and 20 μmol/L PPACK (D-phenylalanyl-prolylarginyl chloromethyl ketone; 1:9 v/v) before loading with 2 μmol/L DiOC 6 . Blood was then transferred to a 1 mL syringe and perfused using an Aladdin AL-1000 syringe pump (World precision instruments, United Kingdom) at a shear rate of 1000 s −1 for 2 minutes. Platelets were fixed by perfusion of 4% paraformaldehyde through channels for 4 minutes before nonadherent cells were flushed away with HEPES Tyrode buffer. IBIDI mounting medium was used to preserve fixed platelets for imaging. Thrombus formation was examined by generating confocal z-stacks (1024×1024 pixels, 0.5 μm stack distance) from 5 randomly chosen fields of view using a Leica SP5-II confocal laser scanning microscope attached to a Leica DMI 6000 inverted epifluorescence microscope (Leica Microsystems, United Kingdom).
Quantification of Platelet Aggregation and δ-Granule Secretion
Aggregometry and dense granule secretion assays were completed as previously described. 22 Aggregation results were expressed as % Max Aggregation and δ-granule secretion as Peak ATP release in nmol/L.
In Vivo Thrombus Formation
Quantification of in vivo thrombus formation was performed as previously described. 26 In brief, mice were anesthetized with 100 mg/ kg ketamine and 10 mg/kg xylazine before labeling of platelets by intravenous administration of 100 mg/kg DyLight 488-conjugated anti-GPIbβ antibody (mice weighing over 30 g were excluded from experiments). Carotid arteries were exposed before 15% FeCl 3 -soaked filter paper was placed on the arterial adventitia for 3 minutes. An Olympus BX51WI fixed stage microscope was used to acquire a time lapse of the injury site for 20 minutes, with post-processing of images completed with ImageJ. Background florescence values measured upstream of the injury site were subtracted from thrombus-specific fluorescence, and data are expressed as integrated density values.
Quantification of PI-Leuk Aggregate Formation
Mouse whole blood was anticoagulated with 4% trisodium citrate and 2000 U/mL Heparin (1:10 v/v) before incubation with red blood cell lysis buffer (1:5.5 v/v) and agitated for 15 minutes before centrifugation at 500g for 5 minutes. Half the volume of supernatant was aspirated and replaced with red blood cell lysis buffer before further agitation (10 minutes) and centrifugation. The formed pellet was resuspended in modified HEPES-Tyrode solution to double the initial volume of whole blood, before stimulation with indicated concentrations of CRP-XL for 10 minutes. Samples were stained with 0.5 μg PE-CD45 and FITC-CD41 antibodies for 5 minutes before quenching by addition of HEPES-Tyrode buffer (1:9 v/v). Samples were analyzed by flow cytometry using a Becton Dickson Biosciences Accuri C6 Sampler plus. Leukocyte populations were identified according to forward and side scatter profiles. Positive PE and FITC events within the leukocyte region signified PI-Leuk aggregates, with appropriate IgG antibody controls used to determine false-positive results. Results are expressed as the median FITC signal present in the Pl-Leuk gate.
DSS-Induced Ulcerative Colitis Model
Ten 8-to 10-week-old RalAB WT and DKO mice littermate pairs were subject to a week of acclimatization before their drinking water was replaced with a 5% DSS solution. Over a 10-day period, mice were given ad libitum access to the DSS solution while being monitored for clinical signs of colitis including bodyweight loss, loose stools, and presence of occult or gross blood in stools. Clinical observations were given scores based on severity and subsequently graphed.
Transmission Electron Microscopy
Subcellular mouse platelet morphology was analyzed by transmission electron microscopy. Ultrathin counterstained sections were prepared as previously described. 27 ImageJ was then used to count dense and α-granules in equivalent-sized fields of view.
Lysosomal Secretion
Lysosomal secretion was determined using a β-hexosaminidase assay. Mouse platelets at 2×10 8 platelets/mL were stimulated with indicated concentrations of agonist for 10 minutes at 37°C. Samples were then centrifuged at 650g for 1 minute to isolate releasates. Control total samples were generated by lysing unstimulated platelets with an equal volume of 1% Triton-X before 3 cycles of snap freezing. Twenty microliters of releasate/control was then incubated with 20 μL of 5 mmol/L 4-Nitrophenyl N-acetyl-β-d-glucosaminide made up in citrate phosphate buffer (80 mmol/L Na 2 HPO 4 , 60 mmol/L citric acid, pH 4.2) for 2 hours at 37°C. Reactions were quenched with the addition of 200 μL of 0.1 mol/L NaOH before reading of absorbance at 405 nm in an Opysys MR platereader made by Dynex Technologies (Worthing, United Kingdom).
Statistical Analysis
All statistical analysis was performed with GraphPad Prism 5.03. All data are representative of >3 experiments, represented by mean±SEM (exact number of repeats are detailed in figure legends). Antibody microarray data were n=2, with no statistical test performed ( Figure  I in the online-only Data Supplement). Normality testing was conducted with the use of a Kolmogorov-Smirnov test and supported by graphical inspection of data. t tests and 2-way ANOVA statistical tests were used where appropriate, with Bonferroni post hoc test used for 2-way ANOVAs.
Results
Ral GTPases Bind the Exocyst on Platelet Stimulation
Immunoblotting confirmed expression of the Ral GTPases in both human and murine platelets, 28 with appropriate Ral deletion achieved in all gene-targeted Ral mouse lines ( Figure 1A ). Exocyst expression was confirmed by immunoblotting for components of the complex in platelet lysates alongside positive control lysates ( Figure 1B) . [29] [30] [31] The data demonstrate the expression of the exocyst complex in both human and mouse platelets, supporting published platelet transcriptome studies. 32 Using a RalBP1-GST pull-down approach, we showed that both RalA/B became maximally activated after 1 minute of stimulation with CRP-XL in human platelets ( Figure 1C )-in line with previous findings. 18 Furthermore, we were able to show that Ral GTPases are activated by a panel of platelet agonists including ADP, U46619, CRP, and protease-activated receptor 4-activating peptide (PAR4-AP; Figure 1D ).
To determine if activated Ral GTPases associate with the exocyst complex in platelets, constitutively active mutant forms of RalA (Q75L), RalB (Q72L), and their inactive counterparts (S31N and S28N) 1 were GST tagged and used in a pull-down assay. Active forms of both RalA/B associated with Sec8/EXOC4 in basal and CRP-stimulated conditions ( Figure 1E ), whereas there was no association of the exocyst with the inactive Ral mutants.
Presence of at Least 1 Ral GTPase Is Essential for P-Selectin Expression on the Surface Membrane of Mouse Platelets
Flow cytometry was used to simultaneously measure P-selectin expression and integrin α IIb β 3 activation in mouse platelets. Stimulation of RalA −/− platelets with CRP-XL showed no difference between WT and KO ( Figure 2A and 2D), whereas RalB −/− platelets showed a ≈50% reduction in P-selectin expression when stimulated with 10 μg/mL CRP-XL (P<0.01), with no alteration to integrin α IIb β 3 activation ( Figure 2B and 2E). Analysis of RalAB DKO platelets in these assays showed a ≈85% reduction in P-selectin expression at 3 (P<0.05), 10 (P<0.001), and 30 μg/mL CRP-XL (P<0.001), with no change in integrin α IIb β 3 activation ( Figure 2C and 2F ).
Experiments were repeated with PAR4-AP to determine the agonist specificity of the effects seen for CRP-XL ( Figure 2G and 2H), with DKO platelets showing a ≈60% reduction when compared with WT counterparts (P<0.001). Samples were also prepared with the P 2 Y 12 blocker AR-C66096 (ARC, 10 μmol/L) and stimulated with PAR4-AP to rule out any δ-granule secretion defects contributing to the defect in α-granule secretion, as previously described. 33 However, in the presence of ARC, the reduction in P-selectin expression in RalAB DKO mice is preserved, suggesting no contribution from δ-granule secretion. Importantly, integrin α IIb β 3 activation was not altered in response to PAR4-AP.
Ral Deletion Marginally Alters α-Granule Cargo Levels and Release
The substantial reduction in stimulated P-selectin expression in RalAB DKO platelets suggested a major defect in α-granule secretion, so it was important to quantify α-granule content and release in the RalAB WT and DKO platelets. PF4 and TGF-β release in response to platelet stimulation were assessed by ELISA ( Figure 3A and 3B) . The data, however, indicated no change in PF4 release, with only a small reduction in TGF-β release observed in response to 125 μmol/L PAR4-AP (P<0.05)-suggesting largely unaltered α-granule content release in DKO platelets. These data were further supported by the use of an antibody microarray to assess the effect of Ral deletion on a wider range of α-granule cargo, where relative levels of angiogenesis-associated polypeptides were determined in supernatants isolated from WT and DKO platelets stimulated with 3 μg/mL CRP-XL. Calculated DKO:WT ratios of the most abundant proteins present in samples from 2 separate assays showed no change in levels of released polypeptides between WT and DKO ( Figure I in the online-only Data Supplement). Furthermore, lysosomal secretion as determined by measurement of released β-hexosaminidase was also unaltered in DKO platelets ( Figure II in the online-only Data Supplement).
Because of the observed P-selectin defect, it was important to assess if P-selectin localization was altered on Ral deletion, which we determined by immunofluorescence microscopy ( Figure 3C ). Acquired images show that P-selectin staining in the RalAB DKO is comparable to WT platelets, localizing to granular compartments within the platelet.
Although the localization of P-selectin was unaltered, it was also important to investigate expression levels of α-granule proteins within the RalAB WT and DKO platelets. Immunoblotting showed that P-selectin expression, normalized to loading control GAPDH, was marginally greater in RalAB DKO platelets compared with WT (P<0.05; Figure 3D ). Quantification of α-granule cargo content by ELISA showed no change in PF4 levels, but a marginally elevated level of TGF-β present within RalAB DKO platelets (P<0.05; Figure 3D ). Furthermore, transmission electron microscopy images of RalAB WT and DKO platelets showed no overt difference in morphology or granule numbers ( Figure  IIIA and IIIB in the online-only Data Supplement). Taken together, these results indicate that Ral deletion does not cause major alterations in granule biogenesis or cargo loading.
Comparing Kinetics of α-Granule Secretion Highlights a Major Role for Ral GTPases in P-Selectin Surface Expression
To gain further insight into the α-granule release reaction occurring in RalAB WT and DKO platelets, we monitored levels of P-selectin surface expression, integrin α IIb β 3 activation, PF4 release, and TGF-β release in response to stimulation with 3 µg/mL CRP-XL at predefined time points ( Figure 4A , 4B, 4D, and 4E). In addition, total platelet P-selectin levels on stimulation were determined by Western blotting to address whether P-selectin was lost in response to stimulation in transgenic mice ( Figure 4C ). , and retinal pigment epithelium-1 (RPE-1; 2.5 mg/mL) were probed for exocyst components Sec5, Sec6, and Sec8 alongside human and murine platelet lysates (4×10 8 platelets/mL). C, Human platelets were isolated and stimulated with 1.5 μg/mL cross-linked collagen-related peptide (CRP-XL) for the times indicated. RalBP1 (Ral-binding protein 1)-GST (glutathione sepharose transferase) bead pull-downs, to recover active (GTP-bound) Rals, were blotted for RalA (RalA-GTP row) or RalB (RalB-GTP row). Input lysates were blotted for RalA and RalB, as loading controls, as shown. D, Human platelets were isolated and stimulated for 1 min with agonists indicated, lysed and incubated with RalBP1-GST beads to precipitate active Rals. Pull-downs were blotted for RalA (RalA-GTP row) or RalB (RalB-GTP row). Input lysates were blotted for RalA and RalB, as loading controls, as shown. E, Human platelets were isolated and stimulated with 3 μg/mL CRP-XL for 1 min before lysis and incubation with constitutively active (Q75L, Q72L) or inactive (S31N, S28N) mutant forms of RalA/B-GST beads. Proteins were eluted and probed for the exocyst component Sec8. Data shown are representative of 3 independent experiments.
As determined by flow cytometry, we see an increasing difference in P-selectin surface exposure between the RalAB WT and DKO samples over time (P<0.001), with a ≈90% reduction in P-selectin surface exposure observed in the RalAB DKO samples by 30 minutes (Figure 4A ). Measured simultaneously, we observed no change in integrin α IIb β 3 activation at the same time points (Figure 4B ). These data are further supported by real-time monitoring of P-selectin exposure and integrin α IIb β 3 activation, again showing a marked reduction in P-selectin exposure over 15 minutes in RalAB DKO platelets, but no change in integrin α IIb β 3 activation ( Figure IVA and IVB in the online-only Data Supplement). In addition, Ral deletion did not lead to an alteration in total P-selectin levels on stimulation with 3 µg/mL CRP-XL or 125 µmol/L PAR4-AP ( Figure 4C ). (DKO; C, F, G, H) . Mouse platelets (5×10 7 platelets/mL) were incubated with phycoerythrin (PE)-conjugated anti-integrin α IIb β 3 and fluorescein isothiocyanate (FITC)-conjugated anti-CD62P/P-selectin antibodies before stimulation with indicated concentrations of cross-linked collagen-related peptide (CRP-XL; A-F) and protease-activated receptor 4-activating peptide (PAR4-AP). For some experiments, shown in G and H, platelets were pretreated with 10 μmol/L ARC for 10 min. Data for A-F are mean values±SEM (n=7) and G, H are mean values±SEM (n=4). Statistical analysis was performed by 2-way ANOVA with Bonferroni post hoc test (***P<0.001, **P<0.01, *P<0.05).
Finally, measurement of PF4 and TGF-β release by ELISA over the same time points in response to 3 µg/mL CRP-XL highlighted no significant difference between RalAB WT and DKO ( Figure 4D and 4E) . Combined with data from Figure 3 , these results indicate no major differences in soluble cargo release profiles of RalAB WT and DKO platelets, but a severe defect in P-selectin surface expression.
Ral Deletion Reduces δ-Granule Secretion in Response to Submaximal Platelet Stimuli, but Does not Affect Aggregation or Thrombus Formation
Lumi-aggregometry was used to measure δ-granule secretion and platelet aggregation in response to platelet stimulation ( Figure 5A and 5B). Deletion of RalA or RalB alone had no effect on δ-granule secretion or aggregation ( Figure V in the online-only Data Supplement). RalAB DKO mice showed a small reduction in δ-granule secretion in response to 0.6 μg/ mL CRP (P<0.01) and 125 μmol/L PAR-4 AP (P<0.05), but this did not translate to a significant reduction in measured platelet aggregation.
Similarly, deletion of RalA or RalB did not alter thrombus formation in vitro ( Figure VI in the online-only Data Supplement), and although thrombus volume and surface area were marginally reduced in the RalAB DKO platelets, this was not found to be significant ( Figure 5C through 5E). Measurement of in vivo thrombus formation in a ferric chloride injury model again showed no change in the rate or extent of thrombus formation ( Figure 5F through 5H) . Furthermore, it is important to note that platelet Ral deletion has no effect on whole blood hematology values or platelet surface expression of CD41, GPVI, GPIb, and integrin α 2 ( Figure IIIC and IIID in the online-only Data Supplement), which could mask any alterations in aggregation and thrombus formation.
PI-Leuk Interactions Are Reduced in RalAB DKO Mice When Compared With WT
Platelet P-selectin is required for the initial tethering of activated platelets to leukocytes and endothelial cells. 34, 35 This Figure 3 . Ral deletion marginally alters α-granule cargo levels and release. Secretion of PF4 (platelet factor 4; A) and TGF (transforming growth factor)-β (B) from cross-linked collagen-related peptide (CRP-XL) and protease-activated receptor 4-activating peptide (PAR4-AP)-stimulated RalAB wild-type (WT) and double knockout (DKO) platelets (2×10 8 platelets/mL) was determined by ELISA and are displayed as a percentage release of total platelet content. Platelets were stimulated with indicated concentrations of agonist before releasates were isolated by centrifugation of samples at 650g for 1 min. Data shown are mean±SEM (n=5), statistical analysis-2-way ANOVA with Bonferroni post hoc test (*P<0.05). C, Platelets were isolated from RalAB WT and DKO mice and fixed before spotting on coverslips and permeabilization with 0.2% Triton-X. Samples were immunostained with ActinGreen (yellow) and goat anti-mouse P-selectin and anti-goat Alexafluor 642 (magenta). Samples were visualized by confocal microscopy, with multiple z-stacks shown in extended focus. Images are representative of 3 separate experiments (n=3). Scale bar is equal to 1 μm. D, Total P-selectin content relative to GAPDH in platelet lysates was determined by Western blotting and densitometry. Total TGF-β and PF4 content was determined by ELISA. Bars represent mean±SEM (n=3-5). Statistical analysis was performed by unpaired t test (*P<0.05).
tethering allows leukocytes to be recruited to inflamed tissue through extravasation, which contributes to the development of pathologies such as inflammatory bowel disease and rheumatoid arthritis. 36, 37 As platelet Rals regulate stimulated P-selectin expression on the platelet membrane, it was possible that PI-Leuk interaction was disrupted for RalAB DKO platelets.
To determine if these interactions were altered, we measured PI-Leuk aggregate formation in response to platelet stimulation by CRP-XL ( Figure 5 ). Whole blood from RalAB WT and DKO mice was subjected to red blood cell lysis before incubation with increasing concentrations of CRP-XL. Leukocytes and platelets were stained with CD45-PE and CD41-FITC before quenching of the reaction and subsequent analysis by flow cytometry. Appropriate IgG control samples were used to prevent measurement of false-positive events, allowing for generation of quadrant plots where single events positive for both platelets (FITC) and leukocytes (PE) would be present in the top right quadrant-within the Pl-Leuk gate ( Figure 5B ). In Figure 5C , representative data from basal and CRP-stimulated WT/DKO mouse lines illustrates a reduced shift in FITC signal within the Pl-Leuk gate in the DKO sample on stimulation, signifying platelets bound to leukocytes. Measurement of Median FITC within Pl-Leuk in all samples showed a ≈70% reduction in PI-Leuk interaction in the DKO mouse line, when compared with WT (P<0.001), signifying fewer platelets bound to individual leukocytes in RalAB DKO samples ( Figure 5D ). Overall, these results suggest that platelet Rals are critical for mediating this response, and may indicate a major role for these GTPases in inflammatory processes.
To further explore the role platelet Rals play in leukocyte extravasation and inflammatory conditions in vivo, RalAB WT and DKO mice were subject to a DSS-induced model of ulcerative colitis, where drinking water was replaced with 5% DSS over a 10-day period as previously described. 38, 39 The DSS model was chosen in particular because of previous studies highlighting the model's sensitivity to the presence of platelet-mediated leukocyte extravasation, as well as P-selectin function. [40] [41] [42] Mice were monitored for symptoms associated with DSS-induced ulcerative colitis including bodyweight loss, Figure 4 . Investigating the kinetics of α-granule secretion in RalAB wild-type (WT) and double knockout (DKO) platelets. Flow cytometry was used to determine P-selectin expression on the surface membrane (A) and integrin α IIb β 3 activation (B) in RalAB WT/DKO platelets over a 30-min period. Mouse platelets (5×10 7 platelets/mL) were incubated with phycoerythrin (PE)-conjugated anti-integrin α IIb β 3 and fluorescein isothiocyanate (FITC)-conjugated anti-CD62P/P-selectin antibodies before stimulation with 3 µg/mL cross-linked collagenrelated peptide (CRP-XL). Sample was then fixed with an equal volume of 2% paraformaldehyde after 0, 2, 5, 10, and 30 min of stimulation. C, Platelet P-selectin levels after stimulation were determined by Western blotting. Platelets (4×10 8 platelets/mL) from RalAB WT and DKO mice were stimulated with 3 µg/mL CRP-XL or 125 µmol/L protease-activated receptor 4-activating peptide (PAR4-AP) for 10 min before isolation by centrifugation. Supernatant was removed before pelleted platelets were resuspended and lysed. Platelet lysates were then probed for P-selectin, with GAPDH used as a loading control. Secretion of PF4 (platelet factor 4; D) and TGF (transforming growth factor)-β (E) from RalAB WT and DKO platelets (2×10 8 platelets/mL) over 30 min was determined by ELISA and is displayed as a percentage release of total platelet content. Platelets were stimulated with 3 µg/mL CRP-XL for 0, 2, 5, 10, and 30 min before samples were centrifuged at 650g for 1 min and releasates collected. Kinetic data (A, B, D, E) are mean±SEM (n=5) with statistical analysis performed by 2-way ANOVA with Bonferroni post hoc test (***P<0.001). Blot image (C) is representative of 3 independent experiments (n=3).
stool consistency, and presence of blood in stools, with scores generated based on severity ( Figure VIIA and VIIB in the online-only Data Supplement). An overall clinical score was generated by the addition of bodyweight and stool scores which was used as a measure of the progression of the DSS-induced ulcerative colitis model ( Figure  VIIC in the online-only Data Supplement). Results show a significant decrease in all measured parameters on day 4 of the study, with stool scores also significantly reduced on day 2. Taken together, these results suggest that at early stages of DSS-induced ulcerative colitis, platelet Ral deletion reduces the symptoms associated with the progression of the pathology. Although the study was performed for 10 days, by day 8 over half the RalAB WT mice had to be culled because of reaching humane end points and for that reason data from the rest of the study are not shown. On termination, colons were dissected from mice and measured lengthways as a metric of gross pathology-revealing no significant alteration in terminal pathology (data not shown). , and protease-activated receptor 4-activating peptide (PAR4-AP) for 5 min with constant stirring. C, Whole blood from RalAB WT and DKO mice was incubated with 2 μmol/L DiOC 6 before being flowed through a collagen-coated chamber (1000 s −1 for 2 min). Adherent platelets were fixed and representative images shown. Quantification of total thrombus volume (μm 3 ; D) and surface area covered (μm 2 ; E) is also shown. F, A ferric chloride carotid injury model (described in Materials and Methods) was used to evaluate in vivo thrombus formation real time in RalAB WT and DKO mice. Accumulation of fluorescently labeled platelets at the site of injury is shown by mean integrated fluorescence over 15 min (F), end point (at 15 min) integrated fluorescence (G) and area under curve (at 15 min, H). For A, B, data are mean values±SEM (n=4-7); statistical analysis-2-way ANOVA with Bonferroni post hoc test (**P<0.01, *P<0.05). For C-E, data are mean values±SEM (n=7); statistical analysis-unpaired t test. For F-H, data are mean values±SEM (n=9); statistical analysis-unpaired t test. Unpaired t tests (D, E, G, H) found no significant difference between WT and DKO. AU indicates arbitrary units.
Discussion
Ral GTPases are important drivers of cell proliferation and metastasis in multiple human cancers and as such are key targets for development of novel anticancer therapies. In addition, they have been shown to regulate cell adhesion and membrane trafficking including exocytosis, and so it was important to determine their contribution to platelet function. Here, we showed that the 2 genes had overlapping and largely mutually redundant roles in regulating P-selectin externalization, suggesting a role in regulating α-granule secretion. Surprisingly, however, dual Ral deletion had no overt effect on release of α-granule content, while substantially blocking P-selectin surface expression. This has implications for the effects of Ral blockade on platelet function, which may specifically abrogate PI-Leuk interaction and subsequent inflammatory responses, without significantly affecting platelet function in thrombosis. This would allow the development of targeted therapies for diseases of platelet-mediated inflammation.
In the present study, we showed the expression of RalA and RalB in both human and mouse platelets, generating the first genetically modified mouse lines with platelet-specific deletion of RalA, RalB, and both together ( Figure 1A ). Previously published work showed that both RalA/B became maximally activated 1 minute after platelet stimulation and were activated by numerous platelet agonists, 18 and our data in Figure 1C and 1D are consistent with these findings. As one of the main effectors of Rals is the exocyst complex, 4,5,43 we used GST-bound constitutively active and inactive forms of Ral GTPases to pull down interactors and were able to confirm that active Ral GTPases bind the exocyst complex on activation ( Figure 1E ). It is therefore likely that Rals mediate their activity in platelets through activation of the exocyst complex.
Quantification of P-selectin expression by flow cytometry revealed significant defects in both RalB KO and RalAB DKO platelets, suggesting that Ral GTPases play key roles in α-granule secretion (Figure 2) . The results also imply a degree of functional redundancy between the 2 GTPases, as the reduction in α-granule secretion observed in the RalAB DKO (≈85%) was greater than the sum of reduction in both RalA KO (0%) and RalB KO (≈50%) mouse lines. Data also indicate that RalB is the dominant isoform of Ral GTPases regulating α-granule secretion, with RalA only playing a minor role. Further investigation into RalAB DKO α-granule secretion showed that this defect in secretion was not specific to GPVI agonists, with platelet stimulation by the PAR4-AP revealing a ≈60% reduction in P-selectin externalizationsuggesting that RalAB DKO platelets can sustain a moderate level of P-selectin surface expression when stimulated with high levels of a potent platelet agonist. As defects in δ-granule secretion are known to contribute to α-granule secretory defects, 33 the P2Y12 blocker ARC was used to block any platelet activation by ADP released from δ-granules. Again, the defect observed without ARC was preserved, with a major reduction observed in the RalAB DKO mouse line. Integrin α IIb β 3 activation was not altered in any of these assays, implying that the P-selectin surface expression defect cannot be attributed to a defect in platelet activation or integrin signaling. Taken together with previous studies, 19, 44 the data indicate that the α-granule secretory defects observed are likely to be because of diminished Ral-exocyst interaction. Although P-selectin surface expression was reduced, it was important to assess the release of nonmembrane-bound, soluble α-granule cargoes to gain a full understanding of the secretory defect. Interestingly, quantification of TGF-β and PF4 secretion from DKO platelets was largely unchanged from WT, with only TGF-β release in response to 125 µmol/L PAR4-AP being significantly reduced by ≈20%, suggesting broadly normal cargo release ( Figure 3A and 3B) . Antibody microarray analysis of releasates isolated from stimulated WT and DKO platelets supported this, showing no alteration in the release of other known α-granule cargoes such as angiopoietin-1, endostatin, platelet-derived growth factor, stromal cell-derived factor 1, thrombospondin-2, and VEGF (vascular endothelial growth factor) 10, 45 ( Figure I in the online-only Data Supplement). In addition, we investigated the localization of P-selectin in WT and DKO platelets by immunofluorescence microscopy ( Figure 3C ). Acquired images show similar P-selectin patterning in both WT and DKO, with P-selectin appearing to be localized to granular compartments within the platelet. Acquired transmission electron microscopy images of the WT and DKO platelets revealed no alteration in morphology or granule count ( Figure IIIA and IIIB in the online-only Data Supplement)-implying no role for Rals in controlling platelet morphology.
It was important to rule out any roles for Rals in granule biogenesis or cargo loading. Determination of relative P-selectin levels in platelet lysates by immunoblotting showed a small increase in RalAB DKO platelets compared with WT ( Figure 3D ). Measurement of total PF4 content by ELISA showed no difference between WT and DKO platelets, whereas TGF-β levels were slightly elevated. The data suggest that Ral GTPases play no role in platelet granule biogenesis or cargo expression.
To further investigate the α-granule secretory events occurring in RalAB DKO platelets, we monitored P-selectin surface expression, integrin α IIb β 3 activation, PF4 release, and TGF-β release over time in response to CRP-XL stimulation ( Figure 4 ). Results revealed a substantial reduction in P-selectin surface expression over 30 minutes in RalAB DKO platelets when compared with WT ( Figure 4A ; Figure IVA in the online-only Data Supplement). Conversely, simultaneous measurement of integrin α IIb β 3 activation showed no difference between mouse genotypes ( Figure 4B ; Figure IVB in the online-only Data Supplement). Examining the P-selectin data shows a small increase over time in DKO P-selectin surface expression-suggesting that some antibody binding to platelet P-selectin does occur on stimulation. It is, however, not possible to deduce whether this antibody binding occurs on a transient fusion event of the α-granule, where α-granule P-selectin is briefly exposed to the external milieu or if a low level of P-selectin surface expression takes place. In addition, we observed no early appearance or spiking of the P-selectin signal in the DKO platelets in our kinetic studies ( Figure 4A ; Figure IVA in the online-only Data Supplement), which could have otherwise suggested an increased rate of P-selectin shedding or clearance. Supporting this observation, assessment of total platelet P-selectin levels after stimulation with either CRP-XL or PAR4-AP showed no reduction in P-selectin levels in WT or DKO samples ( Figure 4C ). These data again suggest that Ral deletion does not increase P-selectin shedding from the surface membrane, and P-selectin is retained within/ on the platelet membrane on stimulation in both mouse lines. Finally, both PF4 and TGF-β release over 30 minutes were not significantly altered by Ral deletion. Interestingly, there seems to be a disparity in the release kinetics of these 2 α-granule cargoes, with PF4 release peaking at 10 minutes, earlier than TGF-β release. This could be explained by PF4 being sequestered back into the platelets at a faster rate than TGF-β, or that PF4 was broken down faster than TGF-β after release. There is also the possibility of differential α-granule secretion causing a faster release of PF4 compared with TGF-β, through release from distinct subsets of α-granules. 17, 46 Taken together, the absence of Ral GTPases causes an α-granule secretory defect where soluble cargoes are released, but P-selectin is not substantially expressed on the surface membrane. We think that there are 2 plausible explanations for these observations: (1) Rals may regulate differential secretion of α-granules with differential P-selectin content or (2) Rals regulate kiss-and-run exocytosis where fusion of granule with target membrane is transient. Differential α-granule secretion, as described previously, 17, 46 could cause the secretion of different subpopulations of α-granules lacking or possessing P-selectin on their membranes. There is already evidence to suggest that P-selectin is differentially packaged from von Willebrand factor in mouse platelets, indicating the presence of distinct subpopulations of P-selectinpositive and P-selectin-negative α-granules. 47 The deletion of Ral GTPases, which localize to secretory granules, 4 could therefore result in diminished secretion of P-selectin-positive α-granules, but not P-selectin-negative granules containing the released peptides we detected (Figure 2 ; Figure I in the online-only Data Supplement). Alternatively, the phenomenon could reflect kiss-and-run exocytosis, where a full fusion event of the secretory granule does not occur-this has previously been shown in platelets using single-cell amperometry. 48, 49 Not dissimilar to chromaffin cells, 50 platelet kiss-and-run exocytosis may occur on cell stimulation and be the favored fusion event in the absence of Ral GTPases. In this way, transient reversible fusion of α-granules with the plasma membrane may occur, but full irreversible fusion does not. This would allow for soluble cargo to be released, but α-granule membrane incorporation into the surface membrane would not occur. In a similar vein, it is also plausible that Ral GTPases play a role in the docking of α-granules, comparable to a suggested role for calpain in platelets. 51 Measurement of δ-granule secretion and aggregation showed no significant difference in single Ral knockout mouse lines ( Figure V in the online-only Data Supplement). RalAB DKO platelets did, however, show a small reduction in δ-granule secretion in response to submaximal concentrations of CRP-XL and PAR4-AP ( Figure 5A ), similar to the observed defect in TGF-β secretion ( Figure 3B ). It should also be considered that this δ-granule secretory phenotype may alter α-granule release as previously shown, 33 which could explain the observed reduction in TGF-β release. Overall, our findings suggest that Ral GTPases play a limited role in the regulation of δ-granule secretion, contrary to a previous study which showed that interruption of Ral-exocyst interactions in permeabilized human platelets reduced δ-granule secretion by ≈70%. 19 The difference with our study may result from the very different technical approaches used. It is also possible, however, that there are species differences between human and mouse platelets. The previous study does, however, indicate that Ral GTPases increase the sensitivity of δ-granule secretion in response to low-level platelet stimuli, which is consistent with our data, and may be mediated by a calciumsensing role for Ral GTPases.
Although the observed P-selectin and δ-granule secretory defects did not translate into reduced aggregation or thrombus formation responses ( Figure 5 ), it is interesting to note that previous studies have implied a role for P-selectin in thrombus formation. [52] [53] [54] This may be because of a difference in models used in previous studies, where P-selectin −/− mice or P-selectin-blocking antibodies have been used to halt P-selectin function. As the RalAB DKO mice here are generated as platelet specific using a floxed conditional allele, endothelial cell function and endothelial P-selectin expression 55 are not disrupted-in contrast to P-selectin −/− mice or when using blocking antibodies. We show RalAB DKO platelets also express small amounts of surface P-selectin when stimulated with high concentrations of potent agonist ( Figure 2G ), suggesting that P-selectin function is not completely ablated in our mice. In addition, because the major drivers of platelet aggregation and thrombus formation (integrin α IIb β 3 activation and δ-granule secretion 56, 57 ) are largely unaltered in the RalAB DKO mice, this may also help explain why arterial thrombus formation is normal in these mice.
It was important to explore the effect of reduced surface P-selectin expression on PI-Leuk binding ( Figure 6 ). RalAB DKO samples showed a ≈70% reduction in the PI-Leuk interactions, as a result of reduced P-selectin exposure. 58, 59 These results strongly indicate roles for platelet Ral GTPases in inflammatory responses, so we chose to investigate platelet Ral deletion in vivo using a DSS-induced ulcerative colitis model, because of evidence directly linking platelet α-granule secretion to inflammatory bowel disease and Crohn's disease. [60] [61] [62] Clinical observations associated with symptoms of DSS-induced ulcerative colitis including weight loss, stool consistency/diarrhea, and presence of blood in stools were significantly reduced in RalAB DKO mice in early stages of the study ( Figure VII in the online-only Data Supplement). This is likely to be because of reduced PI-Leuk interactions in the RalAB DKO mice and a subsequently slowed rate of leukocyte extravasation. Although by day 6 of the study, there was no significant difference in clinical scores between RalAB WT and DKO, results from days 2 and 4 point to a role for platelet Rals in the early stages of the inflammatory process in this model. Although there is evidence to suggest that the PF4 promoter model used in this study could lead to Cre expression in cells in the distal colon, 63 the proportion of cells expressing Cre is not determined. With this in mind, we performed an additional control experiment comparing PI-Leuk interactions in Cre expressing and nonexpressing mice, with results showing that the presence of the Cre-PF4 promoter does not alter PI-Leuk interactions ( Figure VIII in the onlineonly Data Supplement). It would, however, be ideal to include in this study mice in which Cre was selectively expressed in colon epithelial cells, but in the absence of a clean promoter system for such a study, we cannot convincingly assign phenotype solely to platelet-specific deletion of Rals. The results do, however, highlight the possibility that platelet-expressed Ral GTPases could be targets for the treatment of disorders associated with PI-Leuk interaction. Finally, these results also raise questions on the use of Ral inhibitors in the treatment of cancer 2 and would need further investigation if the use of these drugs significantly altered platelet or leukocyte function.
In conclusion, we have identified that platelet Ral GTPases are key regulators of P-selectin surface expression, playing only a minor role in regulating the release of soluble platelet cargoes. We propose 2 potential mechanisms: differential secretion of P-selectin-positive α-granule subsets or kiss-and-run exocytosis. The resultant major defect in platelet P-selectin expression in the absence of RalAB induces a marked defect in PI-Leuk interaction. Pf4-Cre + RalA/B flox mice showed reduced symptoms in early stages of inflammatory bowel disease, in a mouse model system. Platelet Ral GTPases could therefore form a novel target for modulating inflammatory disease in conditions where platelet P-selectin surface expression plays an important role.
